Fukuda et al. reported that AIM2 promoted tumor growth with the increase of Treg proportion and decrease of CD4+ effector T cells and without changes in the numbers of CD8+ or CD4+ T cells and DC in the melanoma microenvironment in mouse models. The gene discussed is CD4; the disease is melanoma.